In January, Randy Hillard was part of the U.S. Food and Drug Administration committee that considered the first application for a “biosimilar” medication. In this guest post, he describes patients’ role in the drug approval process and how the committee’s decision could influence cancer care in the future. Read More
Blog
June 9, 2015 Randy Hillard, MD
June 4, 2015 Cat Snyder, ASCO staff
In this podcast, experts Charles Ryan, MD, and Thomas Powles, MD, talk about bladder cancer treatment, including some of the new approaches that are being developed. Read More
June 2, 2015 Amber Bauer, ASCO staff
Two out of three people now live at least five years after being diagnosed with cancer, but there is still more to be done. Researchers at the 2015 ASCO Annual Meeting showed how new treatment options can continue to improve and lengthen the lives of people with both rare and common cancers. Read More
May 30, 2015 Amber Bauer, ASCO staff
This year, President Obama has focused attention on treatments and tools that help doctors tailor medical care for individual patients. Research presented at the 2015 ASCO Annual Meeting shows how targeted therapies can be used to improve the care of people with a number of different types of blood cancer. Read More
May 29, 2015 Amber Bauer, ASCO staff
Immunotherapy is one of the hottest topics in cancer research. This year, focus at the ASCO Annual Meeting has been on a type of immunotherapy called PD-1 inhibitors. Learn how these drugs may help improve the treatment of head and neck, liver, and lung cancers. Read More
